You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Exagen will pay Cypress up to $8 million in upfront and milestone payments as well as additional royalty payments for the business.
Under the deal, Marina will receive $750,000 up front, and stands to be paid as much as $27 million in milestones.
The firm offers its Avise PG test as a service for physicians making decisions about methotrexate therapy.
Cypress will pay up to $5 million for the technology, which it plans to use for diagnosis and therapeutic monitoring of lupus patients.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.